World’s top-selling drug going off patent means big bucks for middlemen
As AbbVie’s Humira faces copycat biologics, the biggest beneficiaries will be the middlemen.
Starting next year the highest-grossing drug of all time, AbbVie‘s Humira, will finally face competition from copycat biologics in the U.S.
Select your Category
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more